Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
US8501693B2 · kind B2 · utility
3Cited by
10References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 6, 2007 |
| Grant date | Aug 6, 2013 |
| Priority date | — |
| Expiry date | Mar 11, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to altering the concentration of fibrinogen, specifically, for example, by decreasing fibrinogen concentration. The present invention also relates to methods for improving the cardiovascular risk profile of a subject by decreasing fibrinogen concentration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.